Key result
Isolated CABG using DuraGraft for conduit preservation resulted in a 1-year major adverse cardiac event rate of 6.6% and significantly improved quality of life (P<0.0001).
Why the study?
The study was conducted to determine clinical outcomes and quality of life after contemporary isolated CABG using an endothelial damage inhibitor (DuraGraft) intraoperatively for conduit preservation.
What are the 1-year clinical outcomes and quality of life in patients undergoing contemporary isolated CABG with DuraGraft conduit preservation?
Cohort (n=2,532)
Yes
What are the 1-year clinical outcomes and quality of life in patients undergoing contemporary isolated CABG with DuraGraft conduit preservation?
Contemporary isolated CABG using DuraGraft for conduit preservation is associated with low 1-year clinical event rates and significant improvements in quality of life.
No takes yet. Share an insight, caveat, or question.
Low 1-year MACE rates and QoL gains seen after isolated CABG; leaves open conduit preservation effects pending randomized trials.
Sandner et al. (2023) conducted a cohort in isolated coronary artery bypass grafting (CABG) (n=2,532). Isolated CABG using DuraGraft for conduit preservation was evaluated on composite of all-cause death, myocardial infarction (MI), or repeat revascularization (RR) [major adverse cardiac events (MACE)] at 1 year. Isolated CABG using DuraGraft for conduit preservation resulted in a 1-year major adverse cardiac event rate of 6.6% and significantly improved quality of life (P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: